In a strategic move to enhance its presence in the biopharmaceutical sector, Novo Holdings A/S has secured a majority stake of approximately 60% in Single Use Support, a pioneering Austrian company specializing in bioprocessing solutions. The acquisition underscores Novo Holdings’ commitment to advancing healthcare technologies and marks its first control investment in the DACH region, […]
In a strategic move to enhance its global manufacturing capabilities, Novo Nordisk has announced a significant acquisition from Novo Holdings A/S, involving three fill-finish sites, in a deal worth $11 billion. This acquisition comes as part of a broader transaction where Novo Holdings A/S has agreed to acquire Catalent, Inc., a leading global contract development […]
Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing prophylactic treatments for underserved bleeding and thrombotic disorders. The company anticipates using the proceeds from the round to complete an ongoing phase 1/2 study of its bispecific antibody HMB-001 in Glanzmann Thrombasthenia apart from advancing its upcoming […]
Elo Life Systems, a US-based food ingredient manufacturer, has raised $24.5 million, closing its Series A financing round, to accelerate the development of its natural, plant-based sweetener products. With this investment, Elo Life Systems also plans to advance US regulatory approvals, develop pilot-scale processing capabilities, and market-test its sweetener with consumers. The food technology company […]
Amolyt Pharma, a France-based clinical-stage biotechnology company, has secured €130 million (around $138 million) from a Series C equity financing round led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). The French biotech company anticipates using the funding to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601 and […]
Exscientia, a UK-based artificial intelligence (AI) drug discovery company, has secured $60 million in a Series C financing round led by new investor Novo Holdings, a Danish firm, which is fully owned by the Novo Nordisk Foundation. Existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital also took part in the funding round […]